Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely – White Diamond Research
Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment.